ClinicalTrials.gg
DrugBiological

Sacituzumab tirumotecan clinical trials

Also written SKB264 and MK-2870.

studies test it
113
open now
91
in phase 3
27
first study started
2020

How each study uses sacituzumab tirumotecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sacituzumab tirumotecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Sacituzumab tirumotecan
51
sac-TMT
20
Sacituzumab Tirumotecan (Sac-TMT)
11
Sacituzumab Tirumotecan (SKB264)
6
Sacituzumab Tirumotecan (SKB264) plus Pembrolizumab
2

Development codes

SKB264
47
MK-2870
34

In one entry with another drug

Given together, or one or the other

SKB264+SKB118
2

Studies by the year they started

106 studies that test it; most in 2026 (44); 7 more planned to start later

Studies that test sacituzumab tirumotecan, by start year
YearStudies
20201
20224
20239
202416
202532
202644

Who runs them

Industry 50 · Other 63

Merck Sharp & Dohme LLC (29) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (17) · Tianjin Medical University Cancer Institute and Hospital (8) · Fudan University (6) · Klus Pharma Inc. (3) · Latin American Cooperative Oncology Group (3) · National Cancer Center, Japan (3) · M.D. Anderson Cancer Center (2)

Often tested with

Tested in the same studies.

Tagitanlimab (6) · Anlotinib (5) · Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 (3) · Paclitaxel (2) · Patritumab deruxtecan (2) · Enfortumab vedotin (1) · Prednisone (1) · Prednisolone (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Sacituzumab tirumotecan is the comparator. A study of two new drugs counts under both.

  • 1Ruzaltatug rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Dec 2028
Reaching primary completion within a year · 27, 8 in phase 3

Studies that test sacituzumab tirumotecan, phase 3 first.

Studies

Open first, then newest update. How each study uses sacituzumab tirumotecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 113

See all 113 studies that test sacituzumab tirumotecan →

Given beside what is tested · 5 — sacituzumab tirumotecan is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with sacituzumab tirumotecan

Codes

What other systems call sacituzumab tirumotecan · ClinicalTrials.gg INT014653

  • UNII (FDA) 3DV5TD1VL3SACITUZUMAB TIRUMOTECANOne source FDA
  • NCI Thesaurus C166409Sacituzumab TirumotecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.